论文部分内容阅读
目的:研究吲哚胺2,3-双加氧酶(IDO)在乳腺癌组织中的表达,探讨IDO表达对乳腺癌新辅助化疗疗效的影响。方法:采用免疫组织化学法检测经活检确诊的53例可手术Ⅲa期乳腺癌患者癌组织IDO蛋白表达情况,比较IDO(+)病例与IDO(-)病例对TC和CTF新辅助化疗方案的敏感性。结果:化疗药物对IDO表达具有抑制作用(P<0.05),TC化疗方案组IDO(+)病例的敏感性(77.78%)高于IDO(-)组(28.57%)(P<0.05),CTF化疗方案组IDO(+)病例的敏感性(83.33%)高于IDO(-)组(P<0.05),说明IDO(+)的乳腺癌患者对新辅助化疗更敏感。结论:IDO(+)尚不能作为局部晚期乳腺癌选用新辅助化疗方案的依据,但IDO(+)可作为评估乳腺癌患者选用新辅助化疗方案敏感性的生物指标之一。
Objective: To study the expression of indoleamine 2,3-dioxygenase (IDO) in breast cancer and explore the effect of IDO expression on the efficacy of neoadjuvant chemotherapy in breast cancer. Methods: Immunohistochemistry was used to detect IDO protein expression in 53 cases of operable stage Ⅲa breast cancer patients confirmed by biopsy. The sensitivity of IDO (-) cases and IDO (-) cases to TC and CTF neoadjuvant chemotherapy regimens was compared Sex. Results: The chemotherapeutic drugs inhibited the expression of IDO (P <0.05). The sensitivity of IDO (+) cases in TC chemotherapy group was 77.78% higher than that in IDO group (28.57%) (P <0.05) The sensitivity (83.33%) in IDO (+) cases was higher than that in IDO (-) groups (P <0.05), indicating that IDO (+) breast cancer patients are more sensitive to neoadjuvant chemotherapy. Conclusion: IDO (+) can not be used as a basis for neoadjuvant chemotherapy in locally advanced breast cancer. However, IDO (+) may be used as one of the biomarkers to evaluate the sensitivity of neoadjuvant chemotherapy in breast cancer patients.